ClinicalTrials.gg
RecruitingNCT03067051Updated May 1, 2026

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

A Phase 1/2 interventional study of Verteporfin and SpectraCure P18 System in Recurrent Prostate Cancer, sponsored by SpectraCure AB. Recruiting at 4 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by SpectraCure AB · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2017; still recruiting 9 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
1,189th of 3,023
66 · median 48
Started
2017
with 148 others
Phase 1/2
283 of 3,596
62 open now
Primary completion
2027-07
later than 446 of 971 live
Registered
2,012th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,189th largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 149 that started in 2017, is one of 283 in phase 1/2, reaches primary completion later than 446 of the 971 other live ones, and was the 2,012th registered.

Prostatic Neoplasms

7,047 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.

Read the detailed description

In 2011, more than 200,000 men in North America alone were diagnosed with cancer of the prostate, which makes it one of the most common cancer types. It affects the lives of the subjects in many ways.

After treatment the subjects PSA levels are being closely monitored to detect potential recurrence. A high number of subjects will get recurrent prostate cancer. The treatment options for recurrent cancer are more limited than for primary tumors as secondary treatment partly depends on which treatment the subject has previously undergone.

Treatment of recurrent prostate cancer may, depending on the standard treatment of the primary disease, include the following:

  • Radiation therapy.
  • Prostatectomy for subjects initially treated with radiation therapy.
  • Hormone therapy.
  • Pain medication, external radiation therapy, internal radiation therapy with radioisotopes such as strontium-89, or other treatments as palliative therapy to lessen bone pain.

The objectives of this study is to demonstrate that the use of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI) is a safe treatment for recurrent prostate cancer.

03

Conditions studied

  • Recurrent Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Phase 1 Inclusion Criteria:

  1. Males > 18 years who have gone through external or internal, high dose rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence.
  2. Prostate volume less than 50 cm3 defined by transrectal ultrasound
  3. Subject not eligible for surgery or curative radiotherapy
  4. (ECOG) performance status of 0 or 1
  5. Expected survival ≥ 8 months
  6. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, count ≥ 100,000/mm3
  7. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl
  8. Adequate hepatic function, based on a total ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase () ≤ 3 times the , and alanine transaminase (ALT) ≤ 3 times the upper limit of normal
  9. Signed

Phase 1 Exclusion Criteria:

  1. Patients with locally advanced (AJCC 7th edition T3/T4) or disease
  2. Patients who have been treated with seed implantation brachytherapy
  3. Gleason score ≥ 8 at initial diagnosis
  4. Less than 1 week since surgery (excluding minimal procedures, e.g. vascular access device insertion)
  5. Concomitant infection
  6. Subjects with other severe concurrent disease that in the judgement of the investigator would make the subject inappropriate for entry into this study
  7. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator
  8. for photosensitizer
  9. Porphyria or other diseases exacerbated by light
  10. Known to verteporfin for injection (VFI) or to any of the
  11. Known allergies to porphyrins
  12. Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site
  13. On-going therapy with a photosensitizing agent
  14. Enrolment in another therapeutic clinical study within 3 months prior to randomization and throughout the study.
  15. Subjects with a history of v4 grade 3 or greater or persistent (>1 separate episode or symptoms lasting more than 3 months after initiation of medical intervention) grade 2 proctitis attributed to radiation.

Phase 2 Inclusion Criteria:

  1. Subjects > 18 years who have gone through external or internal, high dose-rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence.
  2. Treatment target volume less than 50 cm3.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  4. Expected survival ≥ 12 months.
  5. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3.
  6. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl.
  7. Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate- oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.
  8. Signed Informed Consent.

Phase 2 Exclusion Criteria:

  1. Subjects with locally advanced (AJCC 7th edition T3/T4), regional pelvic lymph node metastasis, or metastatic disease defined by PSMA PET.
  2. Subjects who have been treated with seed implantation brachytherapy.
  3. Less than 1 week since surgery (excluding minimal procedures, e.g. vascular access device insertion).
  4. Concomitant infection.
  5. Subjects with other severe concurrent disease that in the judgement of the investigator would make the subject inappropriate for entry into this study.
  6. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator.
  7. Contraindication for photosensitizer.
  8. Porphyria or other diseases exacerbated by light.
  9. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients.
  10. Known allergies to porphyrins.
  11. Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site.
  12. On-going therapy with a photosensitizing agent.
  13. Enrolment in another therapeutic clinical study within 3 months prior to randomization and throughout the study.
  14. Subjects with a history of CTCAE v4 grade 3 or greater or persistent (>1 separate episode or symptoms lasting more than 3 months after initiation of medical intervention) grade 2 proctitis attributed to radiation.
  15. Contraindication for MRI/Gadolinium contrast such as: implants, severe renal impairment ( [GFR] \<30 mL/min/1.73m2, or previous contrast reactions.
  16. On-going or planned hormone therapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    PDT and verteporfin dose finding

    Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study. The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer. The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI). The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer .

    Drug: Verteporfin · Device: SpectraCure P18 System

Interventions

  • In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).

    Also known as: Visudyne

  • DeviceSpectraCure P18 System

    Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment related adverse events as assesses by CTCAE v4.0 related to protocol therapy.

    Dose limiting toxicities are defined as grade 3 non-hematologic or grade 4 hematologic toxicities that are possibly, probably or definitely related to PDT.

    Time frame: Within 4 weeks of treatment in each cohort.

  2. Percentage of subjects with negative biopsies.

    Histopathologically tumor-free.

    Time frame: 6 months following PDT.

Secondary outcomes

  1. Damage to the periprostatic tissues including the rectal wall mediated by PDT

    Potential damage to the periprostatic tissue will be evaluated by contrast-enhanced and not-contrast enhanced MRI.

    Time frame: 5-9 days following PDT

  2. Performance of SpectraCure P18 system

    Performance of the SpectraCure P18 system will be evaluated by light dose-volume histograms for the light dose coverage

    Time frame: Dose-volume histograms will be evaluated at month 12

  3. Adequacy of effectiveness

    Effectivity will be evaluated by MRI to determine the extent of necrosis in the prostate

    Time frame: Within 1 week of treatment

  4. Percentage of subjects with remaining localized tumour.

    Evaluated by MRI.

    Time frame: 12 months following PDT.

  5. Percentage of subjects with biochemical failure.

    Failure defined as a rise in PSA level of 2.0 ng/mL or more, over and above the nadir.

    Time frame: 12 months following PDT.

  6. Percentage of subjects with extra prostatic or distant disease.

    Evaluated by PSMA PET.

    Time frame: 12 months following PDT.

07

Study locations

4 of 4 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • James Eastham, MD · Contact
  • Princess Margaret Cancer Centre
    Toronto, Ontario ON M5G 2M9, Canada
    Recruiting
    • Neil Fleshner, MD · Contact
    • Nathan Perlis, MD · Contact416-946-4501
  • Skåne University Hospital
    Malmö, Skåne County, Sweden
    Recruiting
    • Emelie Winell, RN · Contact
    • Anders Bjartell, Prof · Principal investigator
  • Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust
    London, W1W 7TS, United Kingdom
    Recruiting
    • Caroline Moore, Prof · Contact
    • Rebecca Scott, RN · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for Jul 2027, 124 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 124 months is above that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2017
First posted
Mar 1, 2017
StartActual
Mar 21, 2017
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03067051
Lead sponsor
SpectraCure AB
Responsible party
Sponsor
First posted
Mar 1, 2017
Start date
Mar 21, 2017
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Johannes Swartling
Contact
jsw@spectracure.com
+46 (0) 46 16 20 70

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verteporfin

Start the discussion